摘要
目的探讨卡托普利对慢型克山病患者预后的影响。方法慢型克山病患者随机分为卡托普利治疗组和对照组。对照组给予地高辛、螺内酯和双氢克尿噻口服：卡托普利治疗组在对照组治疗基础上加服卡托普利，定期观察并随访。Kaplan-Meier法计算生存率。结果卡托普利治疗组和对照组5年生存率分别为87．0％、57．1％，两组比较差异有统计学意义（x^2=4．468，P〈0．05）。结论卡托普利能显著提高慢型克山病患者5年生存率和生活质量，且经济负担小，安全可靠，值得临床推广应用。
Objective To investigate the long-term efficiency of angiotensin converting enzyme inhibitors captopril in patients with chronic Keshan Disease. Methods 45 patients with chronic Keshan Disease were divided randomly into captopril treated group and control group. Digoxin, spironolactone and hydrochlorothiazide were given to patients in control group, while cases in captopril treated group were additionally given captopril. The survival rate was observed and calculated with log-rank test of the Kaplan-meier analysis. Results In our observing period （8 years to 9 months）, 3 cases were died in captopril treated group and 9 cases were died in control group, 5-year survival rate was significant different between the two groups （X^2 = 4.468, P 〈 0.05 ）. Conclusions Captopril, an angiotensin converting enzyme inhibitors, increases 5-year survival and improves life quality of chronic Keshan Disease in a safe and economical way, and is worth to be widely used.
出处
《中国地方病学杂志》
CAS
CSCD
北大核心
2007年第2期206-208,共3页
Chinese Jouranl of Endemiology
关键词
克山病
卡托普利
治疗
生存率
Keshan Disease
Captopril
Therapy
Survival rate
